Heinz Drexel, Giuseppe M C Rosano, Basil S Lewis, Kurt Huber, Alexander Vonbank, Jörn F Dopheide, Arthur Mader, Alexander Niessner, Gianluigi Savarese, Sven Wassmann, Stefan Agewall
{"title":"随机临床试验的年龄:心血管药物治疗随机临床试验的三个重要方面，以血脂和糖尿病试验为例。","authors":"Heinz Drexel, Giuseppe M C Rosano, Basil S Lewis, Kurt Huber, Alexander Vonbank, Jörn F Dopheide, Arthur Mader, Alexander Niessner, Gianluigi Savarese, Sven Wassmann, Stefan Agewall","doi":"10.1093/ehjcvp/pvz029","DOIUrl":null,"url":null,"abstract":"<p><p>Randomized clinical trials (RCTs) are important and the Gold Standard for drugs in modern cardiovascular (CV) therapy. The cornerstone of RCTs is the recording of hard clinical endpoints instead of surrogates. It is important to select an appropriate endpoint. Efficacy endpoints must be clinically relevant and can be hierarchically divided. A very interesting innovation in endpoint acquisition is the total event paradigm.</p>","PeriodicalId":11995,"journal":{"name":"European Heart Journal — Cardiovascular Pharmacotherapy","volume":" ","pages":"97-103"},"PeriodicalIF":0.0000,"publicationDate":"2020-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1093/ehjcvp/pvz029","citationCount":"7","resultStr":"{\"title\":\"The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials.\",\"authors\":\"Heinz Drexel, Giuseppe M C Rosano, Basil S Lewis, Kurt Huber, Alexander Vonbank, Jörn F Dopheide, Arthur Mader, Alexander Niessner, Gianluigi Savarese, Sven Wassmann, Stefan Agewall\",\"doi\":\"10.1093/ehjcvp/pvz029\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Randomized clinical trials (RCTs) are important and the Gold Standard for drugs in modern cardiovascular (CV) therapy. The cornerstone of RCTs is the recording of hard clinical endpoints instead of surrogates. It is important to select an appropriate endpoint. Efficacy endpoints must be clinically relevant and can be hierarchically divided. A very interesting innovation in endpoint acquisition is the total event paradigm.</p>\",\"PeriodicalId\":11995,\"journal\":{\"name\":\"European Heart Journal — Cardiovascular Pharmacotherapy\",\"volume\":\" \",\"pages\":\"97-103\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1093/ehjcvp/pvz029\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Heart Journal — Cardiovascular Pharmacotherapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/ehjcvp/pvz029\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Heart Journal — Cardiovascular Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/ehjcvp/pvz029","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The age of randomized clinical trials: three important aspects of randomized clinical trials in cardiovascular pharmacotherapy with examples from lipid and diabetes trials.
Randomized clinical trials (RCTs) are important and the Gold Standard for drugs in modern cardiovascular (CV) therapy. The cornerstone of RCTs is the recording of hard clinical endpoints instead of surrogates. It is important to select an appropriate endpoint. Efficacy endpoints must be clinically relevant and can be hierarchically divided. A very interesting innovation in endpoint acquisition is the total event paradigm.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
